Neurocrine Bio. (NBIX) PT Lowered to $104 at Needham & Company
Tweet Send to a Friend
Needham & Company analyst Alan Carr lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $104.00 (from $125.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
